Journey Medical
DERM
14 hedge funds and large institutions have $7.94M invested in Journey Medical in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.74% less ownership
Funds ownership: 15.27% → 14.53% (-0.74%)
9% less capital invested
Capital invested by funds: $8.76M → $7.94M (-$816K)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$334K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$254K |
| 3 |
Millennium Management
New York
|
+$107K |
| 4 |
Renaissance Technologies
New York
|
+$77.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell Capital
Alta,
Wyoming
|
-$221K |
| 2 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$164K |
| 3 |
Goldman Sachs
New York
|
-$124K |
| 4 |
BRWM
B. Riley Wealth Management
Memphis,
Tennessee
|
-$81K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$58K |
DERM Hedge Fund Activity: Q1 2022 in Review
14 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q1 2022, worth a combined $7.94M — down 9.3% from $8.76M a quarter earlier.
Fund positioning in DERM was balanced in Q1 2022: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $334K. The largest seller was Cannell Capital, exiting entirely with an estimated $221K sold.
- 14 institutional investors held Journey Medical (DERM) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $7.94M of Journey Medical stock for Q1 2022, down 9.3% quarter-over-quarter.
- 5 funds opened new Journey Medical positions in Q1 2022 and 5 closed out, a net change of 0 holders.
- The largest Journey Medical buyer in Q1 2022 was Opaleye Management, an estimated $334K added.
- The largest Journey Medical seller in Q1 2022 was Cannell Capital, an estimated $221K sold.
Based on aggregated 13F filings for Q1 2022.